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Gastrointestinal pathologists’ perspective on managing risk in the distal esophagus: 
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Here, we discuss recent updates and a continuing controversy in the diagnosis and 
management of Barrett’s esophagus, specifically the recommendation that the irregular Z-line 
not be biopsied, the diminished status of ultrashort-segment Barrett’s esophagus, the evidence 
basis for excluding and including the requirement of goblet cells for the diagnosis of Barrett’s 
esophagus, and the conclusion that histologically confirmed low-grade dysplasia is best 
managed with endoscopic ablation rather than surveillance.  We reference American and 
British Gastroenterology Society Guidelines throughout, with the thesis that the field is 
converging on the concept of applying scarce medical resources to the diagnosis, 
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management of Barrett’s esophagus, including the recommendation that the irregular Z-line 
not be biopsied, the diminished status of ultrashort-segment Barrett’s esophagus, the evidence 
basis for the requirement of goblet cells for the diagnosis of Barrett’s esophagus, and the 
management of histologically confirmed low-grade dysplasia with endoscopic ablation.   
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As is typically the case when studying a new disease, research efforts on Barrett’s esophagus 
were initially focused on the most obvious and severe cases (i.e., long-segment Barrett’s 
esophagus).  The pendulum inevitably swung toward the study of subtler cases (i.e., short and 
ultrashort-segment Barrett’s esophagus).  As our body of knowledge has matured, efforts are 
now being directed toward the investment of scarce medical resources toward the 
surveillance and treatment of patients most likely to derive benefit.  This natural history of 
the discipline is captured in the form of Gastroenterology Society Guidelines (Table 1).
1–4
   
 Here, we focus on newer developments and a continued area of controversy in the 
diagnosis and management of Barrett’s esophagus, namely the strong discouragement of the 
practice of biopsying an “irregular Z-line,” the diminished status of ultrashort-segment 
Barrett’s esophagus, the necessity (or lack thereof) of goblet cells for the diagnosis of 
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of choice in histologically confirmed low-grade dysplasia.  This is facilitated by additional 
review of the definition and localization of the anatomic gastroesophageal junction, the 
distinction of Barrett’s esophagus from carditis with intestinal metaplasia, and the risk of 
neoplastic progression in various categories of Barrett’s esophagus.  We do not specifically 
discuss areas of longer standing and broad agreement (Table 2).     
Definition and localization of the gastroesophageal junction 
The gastroesophageal junction (GEJ) has been variously defined anatomically, 
manometrically, endoscopically, and histologically.  Barrett’s esophagus is characterized by 
proximal displacement of the squamocolumnar junction (i.e., the Z-line) from the GEJ.  
Current definitions of Barrett’s esophagus require that proximal displacement to extend ≥ 1 
cm.
2,3
  As such, precise localization of the GEJ is imperative, and endoscopic definitions are 
the most clinically relevant.  Into the 1990s, the distal esophagus was described as normally 
lined by cardia-type mucosa, typically 1–2 cm in length but occasionally up to 3 cm.
5
  These 
patients would be described today as having columnar metaplasia of the distal esophagus 
(i.e., Barrett’s esophagus in the United States in the presence of goblet cells; Barrett’s 
esophagus in the United Kingdom, regardless of the presence of goblet cells).  
 Two endoscopic definitions of the GEJ predominate: the upper limit of the gastric 
folds (in the West) and the lower limit of the esophageal palisade vessels (in Japan).  
Validation of the Prague C&M criteria, which describe the circumferential and maximal 
extent of a columnar-lined segment relative to the GEJ, found the upper limit of the gastric 
folds to be a highly reproducible anatomic landmark (κ = 0.88).
6
  Assessment may be 
obscured by a number of factors, including deep inspiration, air insufflation, and atrophic 
gastritis.  Kinjo and colleagues compared the impact of the use of Japanese and Western 
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of any extent not requiring biopsy confirmation) in a series of 110 consecutive upper 
endoscopies, finding Barrett’s esophagus rates of 39% and 26%, respectively, with nearly all 
observed Barrett’s esophagus regions being short segments (i.e., < 3 cm), as well as many 
ultrashort segments (< 1 cm).
7
  Evaluation of the distal extent of the esophageal palisade 
vessels is obscured by reflux esophagitis, which is much more common in the West than in 
Japan.  Amano and colleagues performed an interobserver variability study comparing the 
two definitions in a set of 30 endoscopic photographs and reported κ values of 0.16 using 
Japanese and 0.35 using Western landmarks.
8
  Thus, the Western definition appears 
preferable (at least in the West) owing to its better reproducibility, lack of interference by 
reflux esophagitis, and greater likelihood of identifying Barrett’s esophagus patients more 
likely to benefit from endoscopic surveillance. 
 Histologically, esophageal submucosal glands and associated squamous-lined ducts 
are taken as evidence that tissue is derived from the esophagus, and, thus, associated 
columnar epithelium (e.g., in the same biopsy fragment) is taken to be metaplastic.
9
  
However, these structures are noted in only a minority of biopsies.  Similarly, squamous 
epithelium is taken to be esophageal in nature, and columnar epithelium directly underlying 
squamous epithelium is presumed to be metaplastic.  The muscularis mucosae is typically 
reduplicated in Barrett’s esophagus, and, thus, this finding has also been used to infer that 




The Z-line (squamocolumnar junction) 
Like descriptions of the normal distal esophagus, those of the normal squamocolumnar 
junction have varied over time.   Savary and Miller stated that the normal Z-line is “serrated 
and shows four to six small, long, or short tongues towards the esophagus.”
12
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Riddell related that “the Z-line consists of small projections of red gastric epithelium, up to 5 
mm long and 3 mm wide, extending upward into the pink-white squamous epithelium.”
5
  
These descriptions of the squamocolumnar junction imply that it is inherently irregular. This 
created difficulties in applying earlier definitions of Barrett’s esophagus (e.g., 2011 American 
Gastroenterological Association (AGA) guidelines), which refer to “any extent” of 
metaplastic columnar epithelium in the distal esophagus.
1
  Wallner and colleagues took a 
hard line on the normal Z-line, defining it in their Z-line appearance (ZAP) classification as 
“ZAP grade 0: Sharp and circular.  May be wavelike because of the mucosal folds, but no 
tongue-like protrusions are allowed.”
13
  ZAP grade I constitutes “an irregular Z-line with a 
suspicion of tongue-like protrusions and/or islands of columnar epithelium.”  ZAP grades II 
and III correspond to contemporary endoscopic classifications of short-segment and long-
segment Barrett’s esophagus, respectively.  Implicit in these definitions are use of the upper 
limit of the gastric folds to define the GEJ.  Using this classification in a series of consecutive 
endoscopies in patients with reflux symptoms, Wallner and colleagues found intestinal 
metaplasia in 5.4% of 37 grade 0, 15% of 100 grade I, 58.3% of 12 grade II, and 66.7% of 
three grade III patients.  Thus, two-thirds of gastroesophageal reflux disease (GERD) patients 
in this study had an irregular Z-line, which often demonstrated intestinal metaplasia, and 
patients with a normal Z-line also occasionally showed intestinal metaplasia.  In a subsequent 
study of 53 consecutive non-GERD patients, 26 (51%) were ZAP grade 0, 24 (47%) were 
ZAP grade I, and one (2%) was ZAP grade II; intestinal metaplasia was seen in 11.5% and 
25% of grade 0 and I patients, respectively.
14
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Carditis with intestinal metaplasia (CIM) refers to inflamed gastric-type (i.e., cardiac, 
oxyntocardiac, and occasionally fundic) mucosa with associated intestinal metaplasia in the 
proximal stomach.  The presence of intestinal metaplasia at this anatomic site may be 
attributable to Helicobacter infection, autoimmune atrophic gastritis, or reflux.  Patients with 
Barrett’s esophagus may have concurrent CIM.
15,16
  CIM patients are not typically placed into 
endoscopic surveillance owing to a presumed low risk of neoplastic progression.  Sharma and 
colleagues prospectively identified 76 patients with CIM, comparing them to 177 with short-
segment Barrett’s esophagus.  Rates of prevalent (1.3%) and incident (2.9%) dysplasia in 
CIM were significantly lower than in short-segment Barrett’s esophagus (11.3% and 11.5%, 
respectively).
16
  Morales and colleagues reported rates of prevalent and incident dysplasia in 
28 CIM patients of 0% and 1.4% per year.
17
   
 Given a variety of study protocols, patients described as having CIM are a 
heterogenous group, including those with intestinal metaplasia in the proximal stomach; at 
normal, non-displaced Z-lines; at irregular Z-lines; and even in association with what today 
would be characterized as short-segment Barrett’s esophagus.  For example, some studies 
describe taking cardia biopsies 2 cm distal to the top of the rugal folds (i.e., “true” CIM), 
while many others describe taking biopsies across the squamocolumnar junction, regardless 
of its localization.  
 
Histologic distinction of Barrett’s esophagus from carditis with intestinal metaplasia 
In the recent past, when definitions of Barrett’s esophagus made reference to any extent of 
metaplastic columnar epithelium, pathologists were relied on to distinguish “histologic 
Barrett’s esophagus” from CIM in the setting of endoscopically ambiguous descriptions like 
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tongue of salmon-colored mucosa.”  Srivastava and colleagues’ biopsy study, including 20 
cases of Barrett’s esophagus and 20 cases of CIM (defined in this study as intestinal 
metaplasia in biopsies immediately distal to a straight, non-displaced squamocolumnar 
junction) provided a diagnostic framework in this all-too-common scenario.
9
  They found 
several histologic features to be significantly associated with a diagnosis of Barrett’s 
esophagus, including the aforementioned squamous epithelium overlying columnar 
epithelium with goblet cells (i.e., “buried metaplasia”) and esophageal submucosal glands or 
squamous-lined ducts, as well as diffuse intestinal metaplasia (i.e., involving > 50% of the 
biopsy), incomplete intestinal metaplasia (i.e., intergoblet columnar cells resembling gastric 
foveolar epithelium), hybrid glands (i.e., single glands containing cardia-type cells and goblet 
cells), and multilayered epithelium (i.e., a distinctive epithelium with acid mucous cells 
overlying squamous cells) (Table 3 and Fig. 1).  Buried metaplasia, esophageal submucosal 
glands/squamous-lined ducts, and hybrid glands were found to be specific for Barrett’s 
esophagus.  
 
Intestinal metaplasia at the Z-line 
As discussed above, intestinal metaplasia is often found in biopsies of irregular Z-lines and 
occasionally in biopsies of straight, non-displaced Z-lines (variously abbreviated in studies as 
EGJ-SIM, SIM-GEJ, and IM-GEJ).  Reported rates range from 5% to 43.5% and are typically 
higher in GERD patients and those with irregular Z-lines.
13,14,18–23
  When patients with 
intestinal metaplasia at the Z-line are compared with those with Barrett’s esophagus, they are 
more likely to be non-white and female and to have fewer GERD symptoms, less endoscopic 
evidence of esophagitis, and higher lower esophageal sphincter pressures.  Similar to patients 
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has a very low risk of neoplastic progression.  Horwhat and colleagues followed 34 EGJ-SIM 
patients for a mean of 44 months and found no incident dysplasia.
24
  Jung and colleagues 
followed 86 such patients for a median of 8 years, none of whom developed esophageal 
adenocarcinoma.
25
  Five patients with prevalent low-grade dysplasia had no dysplasia on 
subsequent endoscopies, suggesting these diagnoses may have represented “overcalls” of 
reactive changes.      
 
Irregular (and regular) Z-lines should not be routinely biopsied 
On the basis of the frequent finding of intestinal metaplasia and the negligible (if any) 
increased cancer risk relative to the general population, the non-displaced Z-line, whether 
regular or irregular, should not be routinely biopsied.  The identification of intestinal 
metaplasia in such a biopsy is not currently diagnostic of Barrett’s esophagus, and labeling a 
patient as such and placing them into an endoscopic surveillance has adverse economic 
implications for the patient and for the entire healthcare system.
26
  This conclusion is 
reflected in the 2014 British Society of Gastroenterology and the 2016 American College of 
Gastroenterology guidelines.
2,3
   
 
Ultrashort-segment Barrett’s esophagus is a poorly reproducible diagnosis with a 
negligible cancer risk 
Ultrashort segments of Barrett’s esophagus are defined as those measuring < 1 cm.  The 
distinction of ultrashort-segment Barrett’s esophagus from an irregular Z-line is arbitrary and 
not reproducible, and the presence of intestinal metaplasia in these segments confers no clear 
increase in cancer risk (Table 4).  In the validation of the Prague C&M criteria, while the 
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recognition of segments < 1 cm was found to be only slightly reliable (κ = 0.21).
6
  Thota and 
colleagues recently reported a prospective multicenter cohort of 167 patients with Barrett’s 
esophagus < 1 cm, which they parenthetically equated to “irregular Z-line;” at a median 
follow-up of 4.8 years, none had developed high-grade dysplasia or esophageal 
adenocarcinoma (compared with a 4.4% rate of progression in 1624 patients with ≥ 1 cm of 
Barrett’s esophagus followed for a median of 6 years).
27
  On the basis of the distribution of 
1017 T1 cancers in long-segment, short-segment, and ultrashort-segment Barrett’s esophagus, 
and a literature-derived estimate of the population prevalence of long-, short-, and ultrashort-
segment Barrett’s esophagus of 1.5%, 4.7%, and 14.4%, respectively, Pohl and colleagues 
estimated annual cancer rates of 0.22%, 0.03%, and 0.01% in these endoscopic categories, 
concluding that 450, 3440, and 12,365 such patients would need to be screened to detect one 
cancer.
28
  In both the 2014 British Society of Gastroenterology and the 2017 American 
College of Gastroenterology guidelines, Barrett’s esophagus is defined by the presence of 
columnar mucosa ≥ 1 cm from the GEJ.
2,3
  As briefly referenced above, the 2011 AGA 
guideline defines Barrett’s esophagus as “any extent of metaplastic columnar epithelium.”
1
  It 
is of interest how ultrashort-segment Barrett’s esophagus will be regarded in any future AGA 




Differing viewpoints on the requirement of intestinal metaplasia for the diagnosis of 
Barrett’s esophagus 
The British definition of Barrett’s esophagus does not require the presence of intestinal 
metaplasia (i.e., goblet cells), while the U.S. definition does.
2,3
  The current British guideline 
acknowledges that the presence of intestinal metaplasia modifies the risk of neoplastic 
progression.  It distinguishes “Barrett’s oesophagus with gastric metaplasia only” from 
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columnar-lined mucosa in which goblet cells are not detected, if the absence of goblet cells 
persists on follow-up at 3–5 years, patients may be discharged from endoscopic surveillance.  
The evidence basis of the British and U.S. definitions are reviewed below. 
 
British position: goblet cells are not required for the diagnosis of Barrett’s esophagus  
Implicit in the British position is the belief that columnar mucosa in the distal esophagus, 
regardless of our ability to identify goblet cells, bears a risk of neoplastic progression 
sufficient to warrant placing patients into endoscopic surveillance (or at least warrants one 
endoscopic follow-up).  This position is supported by histologic, epidemiologic, and genetic 
data. 
 The British position acknowledges that, in patients who will subsequently be shown 
to have intestinal metaplasia, it may not be demonstrated at index endoscopy.  It is well 
recognized that goblet cells are more frequently identified in longer segments of columnar 
mucosa, that they vary in density from patient to patient, and that rates of intestinal 
metaplasia detection in columnar-lined segments are a function of the number of biopsies 
taken.  In a set of 1646 individual biopsies from 296 endoscopies in 125 patients with 
columnar lengths of 1–11 cm (mean 4.9 cm), goblet cells were noted in 64% of patients, 51% 
of endoscopies, and only 34% of individual biopsies.
30
  The likelihood of detecting intestinal 
metaplasia at any one endoscopy ranged from 35% if one to four biopsies were taken, to 68% 
(5–8), 74% (9–12), 71% (13–16), and 100% (> 16).  On the basis of the results of this study, 
these investigators recommended a minimum of eight biopsies for the detection of intestinal 
metaplasia in columnar-lined segments, a recommendation that is endorsed in the American 
College of Gastroenterology guideline.
3
  Jones and colleagues had previously shown that, 
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metaplasia on index endoscopy, 23% had intestinal metaplasia on repeat endoscopy.
31
  More 
recently, Khandwalla and colleagues found that, in 80 patients with columnar-lined segments 
(85% < 3 cm) initially negative for intestinal metaplasia, 29% had intestinal metaplasia on 
follow-up.
32
    
 Although it is dogma that esophageal adenocarcinoma arises in association with 
intestinal metaplasia,
33,34
 Japanese and German investigators have shown that the mucosa 
adjacent to small adenocarcinomas in the distal esophagus is frequently gastric type rather 
than intestinal type.  In a series of 141 endoscopic mucosal resections of small, German (i.e., 
Western) esophageal adenocarcinomas, investigators found the directly adjacent mucosa to 
be cardiac or fundic in 71%, intestinal in 22%, and gastric on one side and intestinal on the 
other in 7%; of the 71% entirely flanked by gastric mucosa, 19 had intestinal metaplasia 
elsewhere in the specimen (i.e., goblet cells were present in only 43% of all specimens.
35
  
These findings have recently been reproduced in a series of 100 endoscopic mucosal 
resections of small, Japanese cancers.
36
 
 Two studies demonstrated a similar cancer risk in patients with or without goblet cells 
identified in columnar-lined segments at index endoscopy.  Kelty and colleagues reported a 
retrospective, single-center study of all patients with the finding of columnar mucosa in a 
distal esophageal biopsy from 1980 to 1994.
37
  Upon re-review of biopsies from 712 patients, 
55.1% had and 44.9% lacked intestinal metaplasia.  At a median follow up of 12 years, 4.1% 
with and 3.6% without intestinal metaplasia on index endoscopy had developed esophageal 
adenocarcinoma (P = 0.57).  Similarly, in a retrospective, seven-center study of 612 patients 
with and 322 patients without intestinal metaplasia in non-dysplastic, columnar-lined 
segments at index endoscopy, 3.2% and 3.1%, respectively developed esophageal 
adenocarcinoma at a median follow up of 3.5 years (P = 1).
38
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 Goblet and non-goblet metaplastic columnar epithelium have been shown to harbor 
similar genetic abnormalities.  Chaves and colleagues, in fact, found more frequent gains of 
chromosomes 7 and 18 in non-goblet than goblet columnar cells.
39
  Liu and colleagues, using 
image cytometry, found similar rates of DNA heterogeneity, mild aneuploidy, and 5N-




American position: goblet cells are required for the diagnosis of Barrett’s esophagus  
The American position that goblet cells are required for the diagnosis of Barrett’s esophagus 
is based on the premise that only those segments (≥ 1 cm) exhibiting intestinal metaplasia 
clearly predispose to malignancy.
1,2
  It acknowledges (and addresses) each of the British 
arguments for including those segments without intestinal metaplasia.   
 Instead of (provisionally) labeling patients without demonstrable goblet cells as 
“Barrett’s esophagus with gastric metaplasia only,” the 2016 American College of 
Gastroenterology Guideline withholds any specific diagnosis, stating that a repeat endoscopy 
in 1–2 years to “rule out Barrett’s esophagus” should be considered.
3
  Intestinal metaplasia in 
Barrett segments is known to predominate at the neosquamocolumnar junction, and it is thus 
reasonable to concentrate initial diagnostic biopsies proximally.
41,42
 
 Instead of focusing on the epithelium directly adjacent to early esophageal 
adenocarcinomas, investigators looking for any intestinal metaplasia in endoscopic mucosal 
resection specimens have typically found it.
43,44
  Allanson and colleagues recently reported 
intestinal metaplasia in 79% of 139 such specimens.  Including intestinal metaplasia found in 
previous or subsequent specimens, the frequency was 86%.  Tumors lacking intestinal 
metaplasia tended to be larger and, thus, may have obliterated associated intestinal 
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women and the absence of intestinal metaplasia, with the authors suggesting these may 
represent an etiopathogenetically different disease.  Even Takubo and colleagues 
acknowledge that, in focusing on the gastric mucosa directly adjacent to esophageal 




 Regarding the risk of neoplastic progression in non-goblet columnar mucosa, the best 
epidemiologic evidence suggests no clear increased cancer risk.  In a population-based study 
of all adults in Northern Ireland diagnosed with Barrett’s esophagus from 1993 to 2005, 
including 3179 patients without and 3917 patients with intestinal metaplasia at index 
endoscopy, Bhat and colleagues reported annual incidences of combined high-grade 
dysplasia/adenocarcinoma of 0.07% and 0.38%, respectively.
45
  Westerhoff and colleagues 
reported a single-institution study (University of Chicago) similar to that of Kelty but with a 
very different finding.  Among 690 patients between 1987 and 2008 who had undergone 
biopsy of a columnar-lined segment, 258 (37%) had and 379 (55%) did not have goblet cells 
in columnar mucosa (8% had squamous mucosa only).
46
  In patients with available follow-up, 
dysplasia developed in 8% of 178 patients with and 0% of 118 patients without goblet cells 
(mean follow up of 4.8 years in patients with and 5.8 years in patients without goblet cells).  
Dropping the requirement for goblet cells in this patient cohort would have increased the rate 
of Barrett diagnoses 2.5 fold, with significantly increased costs in the absence of 
demonstrable clinical benefit. 
 Regarding the genetic argument, non-dysplastic Barrett’s esophagus is known to be a 
neoplasm, albeit one with a very low rate of neoplastic progression.  The demonstration of 
genetic abnormalities in non-goblet columnar epithelium is interesting, but, like the 
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Endoscopic eradication is the management of choice in histologically confirmed low-
grade dysplasia 
The 2016 American College of Gastroenterology and the 2017 Revised British Society of 
Gastroenterology guidelines both cite a 2014 multicenter randomized controlled clinical trial 
as the evidence basis for this recommendation.
3,4
  Sixty-eight patients each were randomized 
to radiofrequency ablation or endoscopic surveillance at 6, 12, 24, and 36 months.
47
  All 
diagnoses of low-grade dysplasia were confirmed by central pathology review, and an 
additional endoscopy was performed within 6 months of randomization to exclude prevalent 
endoscopic lesions, high-grade dysplasia, or adenocarcinoma.  Regarding the importance of 
second opinion in new diagnoses of dysplasia, among 511 patients initially screened for 
potential inclusion, low-grade dysplasia was confirmed in 247 (48%), 239 were considered 
indefinite or non-dysplastic (47%), and 25 (5%) were upgraded to high-grade dysplasia or 
cancer.  In the ablation group, one (1.5%) patient progressed to adenocarcinoma, which was 
managed with an endoscopic resection, 98.4% achieved eradication of dysplasia, and 90% 
achieved eradication of intestinal metaplasia.  By comparison, 18 (26.5%) patients in the 
control group progressed to high-grade dysplasia or cancer, including six with cancer (8.8%), 
one of whom required esophagectomy.  Eradication of dysplasia was seen in only 27.9% of 
controls, with no patient achieving eradication of intestinal metaplasia.  Twelve percent of 
patients in the ablation arm developed strictures, all of which were amenable to endoscopic 
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Current American and British Gastroenterology Society Guidelines conclude that the 
irregular Z-line should not be routinely biopsied, that ultrashort-segment Barrett’s esophagus 
is an irreproducible diagnosis with a negligible cancer risk, and that histologically confirmed 
low-grade dysplasia is best managed with endoscopic ablation.  Although American and 
British guidelines continue to differ regarding the requirement of intestinal metaplasia for the 
diagnosis of Barrett’s esophagus, the British guidelines allow patients with short segments of 
columnar-lined mucosa (i.e., ≥ 1 cm and < 3 cm) to be discharged from surveillance if goblet 
cells are not detected at an initial and single follow-up endoscopy.  Future efforts will go 
toward identifying Barrett patients most likely to benefit from surveillance, as > 90% die of 
unrelated causes; decreasing the cost of surveillance efforts; and finding a way to identify the 
85% of esophageal adenocarcinoma patients who present with frank cancer in the absence of 
a personal history of Barrett’s esophagus.   
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Figure 1. Histologic features of Barrett’s esophagus. (A) Diffuse, incomplete intestinal 
metaplasia; (B) buried intestinal metaplasia; (C) squamous-lined duct (*); (D) hybrid gland; 
(E) multilayered epithelium; (F) reduplication of the muscularis mucosae. LP1, inner lamina 
propria; MM1, inner, reduplicated muscularis mucosae; LP2, outer lamina propria; MM2, 
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“The condition in which 
any extent of 
metaplastic columnar 
epithelium that 
predisposes to cancer 
development replaces 
the stratified squamous 
epithelium that normally 
lines the distal 
esophagus.  Presently, 
intestinal metaplasia is 
required for the 
diagnosis of Barrett’s 
esophagus because 
intestinal metaplasia is 
the only type of 
esophageal columnar 
epithelium that clearly 
predisposes to 
malignancy.” 
“Barrett’s esophagus is 
defined as an esophagus 
in which any portion of 
the normal distal 
squamous epithelial 
lining has been replaced 
by metaplastic 
columnar epithelium, 
which is clearly visible 
endoscopically (≥ 1 





“BE should be 
diagnosed when there 
is extension of salmon-
colored mucosa into 
the tubular esophagus 
extending ≥ 1 cm 
proximal to the 
gastroesophageal 






No specific mention of 
“irregular Z-line.” 
“Biopsies are generally 
not recommended if 
there is an irregular Z-
line.”   
“Endoscopic biopsy 
should not be 
performed in the 
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“If biopsy specimens 
are taken . . . they 
should be labelled as 
GOJ and not 
oesophageal.” 
line or a Z line with < 
1 cm of variability.” 
Screening “In patients with 
multiple risk factors 
associated with 
esophageal 
adenocarcinoma (age 50 
years or older, male sex, 
white race, chronic 
GERD, hiatal hernia, 
elevated body mass 
index, and intra-
abdominal distribution 
of fat), we suggest 
screening for Barrett’s 
esophagus.” 
 
“We recommend against 
screening the general 




can be considered in 
patients with chronic 
GORD symptoms and 
multiple risk factors (at 
least 3 of age 50 years 
or older, white race, 
male sex, obesity).  
However the threshold 
of multiple risk factors 
should be lowered in 
the presence of family 
history including at 
least one first-degree 




endoscopy is not 






“Screening for BE may 
be considered in men 
with chronic (> 5 
years) and/or frequent 
(weekly or more) 
symptoms of 
gastroesophageal 
reflux (heartburn or 
acid regurgitation) and 
two or more risk 
factors for BE or EAC.  
These risk factors 
include: age > 50 
years, Caucasian race, 
presence of central 
obesity (waist 
circumference > 102 
cm or waist-hip ratio > 
0.9), current of past 
history of smoking, 
and a confirmed family 
history of BE or EAC 
(in a first degree 
relative.” 
 
“Screening of the 
general population is 
not recommended.”  
Surveillance  No dysplasia: 3–5 
years 
 LGD: 6–12 months 
 HGD in the absence 
of eradication 
therapy: 3 months 
 Carditis with IM or 





 CLE < 3 cm without 
IM or dysplasia: 
repeat endoscopy 
with biopsy––if no 
IM, discharge from 
surveillance 
 CLE < 3 cm with 
IM, without 
dysplasia: 3–5 years 
 No dysplasia: 3–5 
years 
 IND: repeat 




if IND persists–– 
12 months 
 LGD: 12 months 
(endoscopic 
therapy preferred) 
 HGD: endoscopic 
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 CLE ≥ 3 cm without 
dysplasia: 2–3 years 
 IND: single repeat 




 LGD: 6 months (see 
directly below) 






therapy with RFA 
should also be a 
therapeutic option for 
treatment of patients 
with confirmed low-
grade dysplasia in 
Barrett’s esophagus.” 
“Currently, ablation 
therapy cannot be 
recommended routinely 
until more data are 
available.” (2014) 
 
“Patients with LGD 
should have a repeat 
endoscopy in 6 months’ 
time.  If LGD is found 
in any of the follow-up 
OGD and is confirmed 
by an expert GI 
pathologist in at least 
two sets of biopsies, the 
patient should be 
offered endoscopic 
ablation therapy, 
preferably with RFA.” 
(2017) 
“Endoscopic 
eradication therapy is 
the procedure of choice 




No global statement on 
cost-effectiveness 
“There are insufficient 
data to indicate that 
endoscopic screening 
and surveillance for 
Barrett’s oesophagus 
are cost-effective.  
Further studies on non-
endoscopic diagnostic 
methods are awaited.” 
 
“Endoscopic therapy 
for dysplastic Barrett’s 
oesophagus and early 
OAC is cost-effective 
compared with 
oesophagectomy.” 
No global statement on 
cost-effectiveness 
BE, Barrett’s esophagus; CLE, columnar-lined esophagus; GOJ, gastro-oesophageal junction; 
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metaplasia; IND, indefinite for dysplasia; LGD, low-grade dysplasia; OAC, oesophageal 
adenocarcinoma; OGD, oesophagogastroduodenoscopy; RFA, radiofrequency ablation 
 
 
Table 2. Points of broad agreement 
 The “Seattle Biopsy Protocol” should be used, including four-quadrant biopsies every 
2 cm of non-dysplastic and every 1 cm of dysplastic Barrett mucosa, with additional 
targeted biopsies of any lesions (i.e., nodule, plaque, stricture, erosion, ulceration). 
 Dysplasia assessment by H&E morphology remains the gold standard for risk 
stratification in Barrett’s esophagus.  
 Dysplasia assessment is fraught with intra- and interobserver variability, and thus all 
new diagnoses of dysplasia (including indefinite for dysplasia) should be confirmed 
by a second pathologist, ideally one with special expertise in gastrointestinal 
pathology. 
 High-grade dysplasia and intramucosal adenocarcinoma are best managed by 
endoscopic eradication with endoscopic mucosal resection of any visible lesions and 
(preferably) radiofrequency ablation of the remaining Barrett segment. 
 Special attention should be paid to the deep margin of endoscopic mucosal resection 
specimens, with a positive deep margin necessitating additional (and possibly more 
intensive) therapy. 
 Patients should be maintained in endoscopic surveillance after endoscopic eradication 
of Barrett-associated (advanced) neoplasia. 
 Adenocarcinoma invasive beyond the mucosa is typically treated with 
esophagectomy, with endoscopic management potentially applied in poor surgical 
candidates with low-grade tumors confined to the inner third of the submucosa 




Table 3. Histologic features more commonly seen in Barrett’s esophagus (BE) than 
carditis with intestinal metaplasia (CIM) 
Histologic feature Frequency in BE vs. CIM 
Squamous epithelium overlying IM 57%/0% 
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Esophageal glands/ducts 30%/0% 
Incomplete IM 100%/50% 
Diffuse IM 60%/10% 
Multilayered epithelium 70%/15% 
NOTE: Based on Ref. 9. 
 
 










 Meta-analysis including 57 studies, 
11,434 patients, and 58,547 patient-years 
follow up; patients with EAC that 
occurred within 1-year of surveillance 
excluded as “prevalent” 
Short-segment Barrett’s 




 Subset of 16 studies, 967 patients, and 
4,456 patient-years follow up 
Ultrashort-segment Barrett’s 
esophagus/irregular Z-line 




 Single prospective, multicenter cohort 
study including 167 patients followed 
for a median of 4.8 years 
Columnar-lined esophagus 





 Population-based study of all adults 
diagnosed with Barrett’s esophagus in 
Northern Ireland between 1993-2005 
including 3,179 patients without 
intestinal metaplasia at index endoscopy 
and 23,417 patients-years follow up 







 Meta-analysis of 24 studies and 2,694 
patients 
 Rates of progression in component 
studies varied widely (0.02-11.43% for 
EAC; 0.04-26.67 for EAC and/or HGD) 
 Rates of progression influenced by 
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estimated based on LGD/BE ratio; EAC 
rate 0.76% if ratio <0.15 and 0.32% if 
>0.15 





 Meta-analysis of 4 studies, 236 patients, 
and 1,241 patient-years follow up 
Key: CI, confidence interval; EAC, esophageal adenocarcinoma; HGD, high-grade dysplasia; 
LGD, low-grade dysplasia 
 
 
 
